IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,866,908 shares of the company's stock after selling 148,390 shares during the period. Price T Rowe Associates Inc. MD owned 4.47% of IDEAYA Biosciences worth $99,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC raised its stake in IDEAYA Biosciences by 188.8% during the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock worth $5,739,000 after acquiring an additional 118,438 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IDEAYA Biosciences by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock worth $2,527,000 after purchasing an additional 12,029 shares during the last quarter. SG Americas Securities LLC increased its position in shares of IDEAYA Biosciences by 444.2% during the fourth quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock worth $475,000 after purchasing an additional 15,089 shares in the last quarter. KBC Group NV lifted its holdings in shares of IDEAYA Biosciences by 84.6% in the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after purchasing an additional 1,923 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at about $35,000. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded up $0.46 during trading hours on Friday, reaching $20.93. 1,645,235 shares of the company's stock were exchanged, compared to its average volume of 970,038. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $44.42. The company has a market cap of $1.83 billion, a P/E ratio of -6.34 and a beta of 0.51. The company's 50 day moving average is $17.90 and its two-hundred day moving average is $23.05.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. As a group, analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Ratings Changes

IDYA has been the topic of several research analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens reaffirmed an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.